Current News

Walbrook PR is pleased to announce its appointment as Financial PR advisor to LiDCO Group Plc, the cardiovascular monitoring company.

LiDCO Group Plc (AIM: LID) is an AIM listed supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Following on from the full year results announced last month, LiDCO expects significant growth in 2013, driven by higher levels of sales in the UK, their stronger position in the US, and the first full year contribution from LiDCOrapid sales in Japan. Their new product, LiDCOrapidv2, is also expected to contribute to further revenue growth. This product is the first of its kind in the world to be designed specifically for multi-parameter monitoring of both depth of anaesthesia and fluids.

Earlier this month, Ashford and St Peter's Hospitals NHS Foundation Trust incorporated the LiDCOrapidv2 into its enhanced recovery programme for patients undergoing major bowel surgery; as a result patients are now returning home almost a week earlier than they would have been able to in 2008.

Walbrook will advise LiDCO on its communications with the financial media, research analysts and other Small Cap and AIM investors. For more information, please visit:http://www.lidco.com

Paul McManus, Director of Walbrook PR, said: "I am delighted that we are working with the LiDCO team, particularly at a time of significant sales growth and anticipated profitability. LiDCO's technology, which assesses the fluid status of the patient before, during and after surgery, has been shown to significantly improve patient outcomes and reduce hospital recovery time, therefore reducing the overall costs associated with major surgery."